Serve Robotics lifts full-year sales target to $12m and trims spending forecast
The Nasdaq-listed maker of sidewalk and hospital robots reported third-quarter sales of $2.8m and unveiled a unit that supplies its technology to rival robot builders.
Serve Robotics said sales for the quarter ended 30 September 2026 were $2.8m, 313% higher than in the same period of 2025. It reported the figures on 5 November.
Management now expects 2026 revenue of $12m, an increase on its earlier target. It also lowered its forecast for non-GAAP operating expenses, to $150m. By simple arithmetic, planned operating spending is about 12 times the revenue goal, so the business remains at an early commercial stage.
The company closed the quarter with $198.0m in cash and marketable securities. It also introduced Serve Physical AI Services, which makes its technology available to other robot manufacturers. The material available to us gave no detail on pricing, customers or how the offering would be sold, and the full results text was not available for this report.
Why it matters
- Hospital-logistics and supply-chain teams screening robotics vendors can note the disclosed cash balance and revised outlook, though the figures cover the whole company rather than its hospital operations.
- The new service suggests Serve may license its technology to other robot makers as well as running its own robots. Terms have not been disclosed.
- Any healthcare use of the new service will depend on the company's detailed disclosures, which were not available here.
Company's press release (SEC filing): Serve Robotics Inc. /DE/ ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
